$GRAL

GRAIL said the FDA Molecular and Clinical Genetics Panel will meet Sept. 23, 2026 to review its Premarket Approval application for Galleri, a multi-cancer early detection blood test. The submission cites PATHFINDER 2 (25,490 participants, one year) and NHS-Galleri (over 70,000). GRAIL says Galleri detects methylation patterns, with low false positives and accurate signal origin prediction.

GRAIL, Inc. (Nasdaq: GRAL) said the FDA’s Molecular and Clinical Genetics Panel will meet Sept. 23, 2026 to review its Premarket Approval application for the Galleri multi-cancer early detection blood test. The filing is based on PATHFINDER 2 (25,490 participants, 1-year follow-up) and NHS-Galleri (70,000+ participants).

GRAIL, Inc. (GRAL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex9912026q2earningspressre.htm EX-99.1 Document NEWS RELEASE Exhibit 99.1 GRAIL Reports Second Quarter 2026 Financial Results Q2 Galleri ® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and

Hagens Berman Sobol Shapiro LLP said a securities fraud class action was filed against GRAIL, Inc. (NASDAQ: GRAL), alleging misleading statements about the NHS-Galleri trial design and efficacy and selective promotion of results. The firm cites a Feb. 19, 2026 disclosure that the primary endpoint was not met and follow-up likely needed to be longer, after which GRAL shares fell 50.55% in a day. Lead plaintiff deadline is Aug. 4, 2026.

Grail (GRAL), a multi-cancer early detection test company backed early by Jeff Bezos and Bill Gates, was bought by Illumina in 2021 and spun off in 2024. Its Galleri test results from a UK NHS trial in February did not meet the primary Stage III-IV reduction endpoint, leading to a ~50% stock drop. The article cites a current price around $72 and discusses potential FDA approval and insurer coverage as key catalysts.

Bleichmar Fonti & Auld LLP says a securities fraud class action was filed against GRAIL, Inc. (NASDAQ:GRAL) and executives after the company’s NHS-Galleri trial allegedly failed to support prior statements. The suit cites a ~50.55% stock drop (Feb. 19–20, 2026) and alleges violations of Exchange Act Sections 10(b) and 20(a). Investors have until Aug. 4, 2026 to seek lead-plaintiff status.

GRAIL, Inc. (GRAL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. gral-20260618 0001699031 FALSE 0001699031 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 8-K _____________________________________________ CURRENT REPORT Pursuant to Section 13 or 15

Grail (GRAL) develops the Galleri multi-cancer early detection blood test, which it says screens for more than 50 cancer types. The article cites positive results from NHS Galleri 2 and Pathfinder 2 presented at the 2026 ASCO meeting, including >20% reductions in stage IV diagnoses for 12 cancers and higher detection of early-stage disease. Grail is seeking FDA approval (submitted Jan. 2026) and reported a $93.2 million net loss in Q1 2026.

Partridge Andrew John (Chief Growth Officer) sold 1,491 shares of GRAIL, Inc. (GRAL) at $61.08 on 2026-06-04.

Grail (NASDAQ: GRAL) shares fell after its February NHS England Galleri trial failed to meet the primary endpoint, though it reported fewer Stage IV cancers and some earlier detections. Galleri is not FDA-approved; it’s sold cash-only at $749–$949. Revenue rose from $93M (2023) to $147M (2025) while net loss narrowed. Full-year revenue is forecast to rise 22%–32%.